SARMs and Bulking Diets: What the Research Actually Supports

Key takeaways

What a "SARMs bulking diet" actually refers to

Selective androgen receptor modulators (SARMs) are synthetic compounds that bind androgen receptors with tissue-selective activity intended to preserve anabolic effects on muscle and bone while producing fewer androgenic effects on the prostate, skin, hair, liver, and heart than testosterone or anabolic steroids. Several were evaluated as therapy for cancer cachexia, osteoporosis, and age-related muscle and bone wasting, but none were approved for human use.

Online searches for "SARMs bulking diet" typically combine two separate ideas: a drug marketed to increase muscle mass, and a calorie- and protein-focused eating plan meant to support weight and strength gain. These are treated as a package in fitness forums, but the clinical evidence on SARMs and the nutritional science on bulking come from entirely different bodies of research. Conflating them can obscure how thin the SARMs evidence is for this specific use and how comparatively well-established the nutrition evidence is on its own.

Legal and regulatory status: no approved SARM exists

No SARM has been approved by the FDA for any use, including muscle building, cancer cachexia, or osteoporosis. Several such agents were evaluated as therapy for these conditions, but none were approved for human use, and they are not dietary supplements despite frequently being marketed and sold as such.

The FDA has stated that people who have taken products containing SARMs have suffered life-threatening reactions, including liver injuries requiring hospitalization, and that these products have the potential to cause increased risk of heart attack or stroke, psychosis or hallucinations, sleep disturbances, sexual dysfunction, liver injury and acute liver failure, infertility, pregnancy miscarriage, and testicular shrinkage. The agency has said it continues to receive adverse event reports from SARM users and has noted that the true number of affected consumers is likely higher than reported because these products are not approved drugs and people may not realize their symptoms are related to use, or may not know how to report them.

The FDA has issued warning letters to companies selling SARMs as dietary supplements and pursued criminal actions against distributors, and has said body-building products containing SARMs are unapproved drugs that the agency has not reviewed for safety or effectiveness.

SARMs are also prohibited in sport. The World Anti-Doping Agency's 2026 Prohibited List places selective androgen receptor modulators, including andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23, and YK-11, under section S1.2, "Other Anabolic Agents," which is prohibited at all times and classified as a non-Specified Substance under the WADA Code.

Because SARMs cannot be legally marketed as supplements, products sold under names like ostarine are frequently mislabeled, contain undisclosed ingredients, or turn up as contaminants in other supplements, so a buyer often cannot verify what a product actually contains or at what dose.

What the clinical trial evidence actually shows about muscle and lean mass

The best-studied SARM is enobosarm (also called ostarine, MK-2866, or GTx-024). It has been tested in Phase 1, Phase 2, and Phase 3 trials with reported improvements in lean body mass and measures of physical function and power, though it never reached approval for any of the indications studied.

Enobosarm's largest and most rigorous evidence comes from two identically designed Phase 3 trials, POWER 1 and POWER 2, in patients with stage III or IV non-small-cell lung cancer starting first-line chemotherapy. Around 320 to 325 patients per trial were randomized to enobosarm 3 mg daily or placebo, with lean body mass measured by DEXA scan as a co-primary endpoint alongside a physical function measure (stair climb power). Using the pre-specified responder-analysis method agreed with the FDA, the trials showed mixed results: the lean body mass responder endpoint was only borderline or not statistically significant, and the physical function responder endpoint was not met in either trial. Using a separate continuous-variable analysis, enobosarm showed a statistically significant, consistent effect on lean body mass compared with placebo in both trials at multiple time points. The developer did not obtain regulatory approval on the basis of this data.

Because the pre-specified responder endpoints were not consistently met, this result illustrates a broader pattern in the SARM literature: signals of a lean-mass benefit on some statistical analyses, without a result strong or consistent enough to support approval, and no trial in this program tested outcomes in healthy adults trying to add muscle through diet and training.

Other SARMs marketed for bulking, including RAD-140 (testolone), LGD-4033 (ligandrol), and S-23, have much less completed human trial data on muscle outcomes in healthy adults than enobosarm, and a substantial share of what is publicly known about their real-world effects in people who use them for bodybuilding comes from case reports describing adverse events rather than from controlled trials designed to measure muscle gain.

Overall, no controlled trial of any SARM has enrolled healthy adults using the drug specifically as part of a deliberate bulking diet, and the populations that have been studied, cancer patients undergoing chemotherapy, are not representative of that use case in either physiology or monitoring conditions.

Documented health risks, including liver injury

Liver injury is the most extensively documented harm associated with SARM use outside formal trials. The NIH's LiverTox resource states that although no SARM has been approved for human use, several are available in dietary supplements, either as advertised ingredients or as undisclosed contaminants, and have been implicated in multiple cases of severe cholestatic jaundice resembling classic anabolic-steroid-induced liver injury.

Case series and reviews describe a pattern of SARM-associated liver injury that is typically cholestatic, sometimes with a mixed or hepatocellular pattern, appearing weeks after the person started taking the product and often presenting with jaundice, dark urine, pale stools, and pruritus. Reviewers have noted that SARMs can disrupt liver function through mechanisms that may include oxidative stress, altered lipid metabolism, and direct hepatocellular toxicity, and that this growing body of case-level evidence raises real safety concerns even though the mechanisms are not fully worked out.

A case report and review of RAD-140-associated liver injury noted that in every published case to date, including the authors' own, liver injury resolved after the person stopped taking the drug, with no fulminant liver failure or deaths reported. The same authors concluded that, given the drug's potential hepatotoxicity and its ready availability to consumers, RAD-140 and other SARMs should be used only judiciously and under close clinical supervision until more hepatic safety data become available. A separate case report from a different institution reached a related conclusion: missed or continued use after liver injury develops could plausibly progress toward more severe outcomes, which is why prompt recognition and discontinuation are considered important by the clinicians reporting these cases.

Beyond the liver, the FDA's broader list of documented risks, increased risk of heart attack or stroke, psychosis or hallucinations, sleep disturbances, sexual dysfunction, infertility, pregnancy miscarriage, and testicular shrinkage, reflects the fact that SARMs act on androgen-receptor pathways implicated in classic anabolic steroid harms, even though they were designed to be more tissue-selective. Case literature also documents measurable decreases in total testosterone in men using LGD-4033, RAD-140, and ostarine, consistent with suppression of the body's own hormone production.

The nutrition science behind any bulking diet, independent of SARMs

Separate from any drug, the physiology of gaining muscle through diet is comparatively well studied. Building new muscle tissue is understood to require resistance training as the primary stimulus, along with adequate dietary protein.

A widely cited systematic review, meta-analysis, and meta-regression by Morton and colleagues (2018), which pooled 49 trials and more than 1,800 participants, found that protein intakes at amounts greater than approximately 1.6 grams per kilogram of body weight per day did not further contribute to resistance-training-induced gains in fat-free mass, with the 95% confidence interval around that breakpoint extending to roughly 2.2 g/kg/day. This is the source of the commonly cited practical range of about 1.6 to 2.2 g/kg/day for people trying to maximize muscle gain from training, though later analyses and individual variation mean this figure should be read as an approximate plateau rather than a precise cutoff.

A 16-week controlled trial in resistance-trained males compared two high-protein intakes, approximately 1.6 versus 3.2 g/kg/day, alongside resistance or concurrent training, and examined body composition and markers of liver and kidney function as part of assessing whether higher protein intakes carried metabolic risk in trained individuals. Findings of this kind are part of a broader literature suggesting that higher protein intakes are generally well tolerated in healthy, resistance-trained adults over these timeframes, though evidence over multi-year periods remains more limited.

The size of the calorie surplus needed to support muscle gain, and whether a surplus is strictly required at all, is debated in the literature. Some researchers argue that the body can only synthesize a limited amount of new muscle over a given period, meaning that surpluses beyond what supports that rate of gain are more likely to be stored as fat, while other data suggest lean mass can be gained close to maintenance calories when protein intake and training are optimized. Short-term deficit studies also suggest that being in a pronounced calorie deficit can blunt lean-mass gains. Because the precise numeric relationship between surplus size and the rate of muscle gain has not been established with strong consensus in the literature, general statements about an optimal or maximum monthly muscle-gain rate should be treated as rough approximations rather than settled figures.

Why pairing an unapproved drug with a diet plan does not change the underlying risk

Even a well-constructed bulking diet does not add a validated benefit to an unapproved SARM, because these compounds have not been shown safe or effective for muscle building in healthy people using them this way. The FDA has been explicit that SARMs are unapproved drugs that cannot be legally marketed as dietary supplements in the United States, and that they have not been reviewed by the agency for safety or effectiveness.

Product-quality uncertainty compounds the risk. Because SARMs exist in a legal gray zone, products sold under names like ostarine, RAD-140, or LGD-4033 are not manufactured or tested to pharmaceutical or verified dietary-supplement standards, and a product labeled as a SARM may not reliably reflect what is actually inside it.

Clinical dosing data on SARMs come from short trials in specific patient groups, generally over about three to five months and using doses far lower than many reported real-world users take, sometimes in combination with other compounds. This means there is no established safety margin for the higher-dose, longer-duration, or multi-compound use patterns commonly described among people trying to bulk, which helps explain why case reports of liver injury and other harms have emerged largely from real-world, non-trial use rather than from the controlled studies themselves.

Grading the strength of the evidence

The evidence that enobosarm can affect lean body mass in controlled trials is real but mixed: continuous-variable analyses in the Phase 3 POWER trials showed a statistically significant, consistent effect on lean body mass versus placebo, but the pre-specified responder endpoints for lean mass and physical function were not consistently met, and no regulatory approval followed. The evidence that any SARM translates into a safe or effective bulking strategy for healthy adults is essentially absent, since no trial has tested this population, dose, or duration.

The evidence for serious harm, particularly liver injury, is accumulating through case reports, case series, and mechanistic reviews, and is consistent enough across independent reports that clinicians treating these cases have called for close monitoring and clinical supervision if SARMs are used at all. This evidence has not been quantified in large-scale epidemiological studies, which is itself a reflection of the fact that these products are unapproved and used largely outside monitored clinical settings.

The evidence underlying the nutritional half of "bulking," protein targets and the general principle of resistance training plus adequate energy intake, is comparatively strong and is drawn from randomized controlled trials and meta-analyses in exercising humans. It holds regardless of whether any drug is involved, while the precise size of any needed calorie surplus and the maximum achievable rate of natural muscle gain remain less settled questions in the literature.

Frequently asked

References